Acumen Non Currrent Assets Other vs Inventory Analysis

ABOS Stock

USD 2.65 0.03 1.15%

Acumen Pharmaceuticals financial indicator trend analysis is way more than just evaluating Acumen Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Acumen Pharmaceuticals is a good investment. Please check the relationship between Acumen Pharmaceuticals Non Currrent Assets Other and its Inventory accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acumen Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Acumen Stock please use our How to Invest in Acumen Pharmaceuticals guide.

Non Currrent Assets Other vs Inventory

Non Currrent Assets Other vs Inventory Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Acumen Pharmaceuticals Non Currrent Assets Other account and Inventory. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Acumen Pharmaceuticals' Non Currrent Assets Other and Inventory is -0.26. Overlapping area represents the amount of variation of Non Currrent Assets Other that can explain the historical movement of Inventory in the same time period over historical financial statements of Acumen Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Acumen Pharmaceuticals' Non Currrent Assets Other and Inventory is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Currrent Assets Other of Acumen Pharmaceuticals are associated (or correlated) with its Inventory. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Inventory has no effect on the direction of Non Currrent Assets Other i.e., Acumen Pharmaceuticals' Non Currrent Assets Other and Inventory go up and down completely randomly.

Correlation Coefficient

-0.26

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.

Inventory

Most indicators from Acumen Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Acumen Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acumen Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Acumen Stock please use our How to Invest in Acumen Pharmaceuticals guide.Selling General Administrative is likely to gain to about 19.8 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 83.5 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Income	84K	2.4M	8.2M	8.6M
Net Interest Income	84K	2.4M	8.2M	8.6M

Interest Income Net Interest Income

Acumen Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Short Long Term Debt Total	Common Stock Total Equity	Retained Earnings Total Equity
Total Assets		0.89	0.92	0.99	0.96	-0.73	-0.95	0.94	0.87	0.87	0.02	-0.88	1.0	0.54	0.75	-0.11	-0.84	0.92	0.87	0.08	0.99	1.0	1.0	0.67	-0.56	-0.73
Other Current Liab	0.89		1.0	0.83	0.79	-0.55	-0.88	0.87	0.72	0.82	0.05	-0.91	0.89	0.74	0.81	0.3	-0.57	0.67	0.83	0.48	0.84	0.89	0.88	0.74	-0.61	-0.74
Total Current Liabilities	0.92	1.0		0.86	0.82	-0.58	-0.9	0.89	0.75	0.83	0.07	-0.91	0.91	0.72	0.81	0.23	-0.62	0.71	0.86	0.43	0.87	0.91	0.9	0.74	-0.61	-0.76
Total Stockholder Equity	0.99	0.83	0.86		0.97	-0.76	-0.94	0.94	0.88	0.85	0.04	-0.83	0.99	0.45	0.7	-0.25	-0.9	0.95	0.86	-0.06	1.0	0.99	0.99	0.62	-0.51	-0.72
Net Tangible Assets	0.96	0.79	0.82	0.97		-0.75	-0.96	0.93	0.9	0.9	0.0	-0.86	0.96	0.51	0.7	-0.28	-0.92	0.95	0.9	-0.11	0.96	0.96	0.97	0.68	-0.65	-0.78
Net Debt	-0.73	-0.55	-0.58	-0.76	-0.75		0.63	-0.84	-0.95	-0.41	0.42	0.78	-0.77	0.04	-0.12	0.3	0.63	-0.84	-0.5	0.19	-0.73	-0.77	-0.77	-0.07	0.07	0.57
Retained Earnings	-0.95	-0.88	-0.9	-0.94	-0.96	0.63		-0.93	-0.83	-0.94	-0.17	0.86	-0.95	-0.67	-0.83	0.14	0.87	-0.84	-0.98	-0.05	-0.94	-0.95	-0.94	-0.81	0.75	0.87
Accounts Payable	0.94	0.87	0.89	0.94	0.93	-0.84	-0.93		0.94	0.77	0.0	-0.91	0.96	0.44	0.62	-0.16	-0.81	0.87	0.87	0.03	0.93	0.96	0.96	0.56	-0.49	-0.87
Cash	0.87	0.72	0.75	0.88	0.9	-0.95	-0.83	0.94		0.66	-0.29	-0.9	0.9	0.25	0.39	-0.24	-0.76	0.92	0.72	-0.1	0.86	0.9	0.9	0.36	-0.36	-0.72
Non Current Assets Total	0.87	0.82	0.83	0.85	0.9	-0.41	-0.94	0.77	0.66		0.18	-0.77	0.86	0.81	0.92	-0.03	-0.8	0.76	0.93	0.13	0.86	0.86	0.85	0.93	-0.88	-0.71
Non Currrent Assets Other	0.02	0.05	0.07	0.04	0.0	0.42	-0.17	0.0	-0.29	0.18		0.27	-0.01	0.25	0.43	-0.25	-0.26	-0.19	0.33	-0.16	0.07	-0.01	-0.02	0.39	-0.28	-0.34
Other Assets	-0.88	-0.91	-0.91	-0.83	-0.86	0.78	0.86	-0.91	-0.9	-0.77	0.27		-0.9	-0.58	-0.61	-0.17	0.6	-0.8	-0.78	-0.32	-0.83	-0.9	-0.89	-0.59	0.55	0.73
Cash And Short Term Investments	1.0	0.89	0.91	0.99	0.96	-0.77	-0.95	0.96	0.9	0.86	-0.01	-0.9		0.52	0.72	-0.13	-0.84	0.93	0.87	0.06	0.99	1.0	1.0	0.65	-0.54	-0.75
Net Receivables	0.54	0.74	0.72	0.45	0.51	0.04	-0.67	0.44	0.25	0.81	0.25	-0.58	0.52		0.92	0.46	-0.33	0.28	0.72	0.58	0.48	0.51	0.5	0.95	-0.9	-0.52
Common Stock Shares Outstanding	0.75	0.81	0.81	0.7	0.7	-0.12	-0.83	0.62	0.39	0.92	0.43	-0.61	0.72	0.92		0.17	-0.62	0.51	0.87	0.34	0.73	0.71	0.71	0.98	-0.87	-0.64
Non Current Liabilities Total	-0.11	0.3	0.23	-0.25	-0.28	0.3	0.14	-0.16	-0.24	-0.03	-0.25	-0.17	-0.13	0.46	0.17		0.59	-0.35	-0.15	0.98	-0.22	-0.13	-0.15	0.16	-0.09	0.2
Inventory	-0.84	-0.57	-0.62	-0.9	-0.92	0.63	0.87	-0.81	-0.76	-0.8	-0.26	0.6	-0.84	-0.33	-0.62	0.59		-0.87	-0.85	0.42	-0.89	-0.84	-0.85	-0.59	0.56	0.74
Other Current Assets	0.92	0.67	0.71	0.95	0.95	-0.84	-0.84	0.87	0.92	0.76	-0.19	-0.8	0.93	0.28	0.51	-0.35	-0.87		0.72	-0.21	0.94	0.93	0.94	0.46	-0.41	-0.58
Other Stockholder Equity	0.87	0.83	0.86	0.86	0.9	-0.5	-0.98	0.87	0.72	0.93	0.33	-0.78	0.87	0.72	0.87	-0.15	-0.85	0.72		0.04	0.86	0.87	0.86	0.86	-0.82	-0.92
Total Liab	0.08	0.48	0.43	-0.06	-0.11	0.19	-0.05	0.03	-0.1	0.13	-0.16	-0.32	0.06	0.58	0.34	0.98	0.42	-0.21	0.04		-0.03	0.06	0.04	0.3	-0.2	0.02
Net Invested Capital	0.99	0.84	0.87	1.0	0.96	-0.73	-0.94	0.93	0.86	0.86	0.07	-0.83	0.99	0.48	0.73	-0.22	-0.89	0.94	0.86	-0.03		0.99	0.99	0.65	-0.53	-0.72
Total Current Assets	1.0	0.89	0.91	0.99	0.96	-0.77	-0.95	0.96	0.9	0.86	-0.01	-0.9	1.0	0.51	0.71	-0.13	-0.84	0.93	0.87	0.06	0.99		1.0	0.64	-0.54	-0.74
Net Working Capital	1.0	0.88	0.9	0.99	0.97	-0.77	-0.94	0.96	0.9	0.85	-0.02	-0.89	1.0	0.5	0.71	-0.15	-0.85	0.94	0.86	0.04	0.99	1.0		0.64	-0.54	-0.74
Short Long Term Debt Total	0.67	0.74	0.74	0.62	0.68	-0.07	-0.81	0.56	0.36	0.93	0.39	-0.59	0.65	0.95	0.98	0.16	-0.59	0.46	0.86	0.3	0.65	0.64	0.64		-0.95	-0.64
Common Stock Total Equity	-0.56	-0.61	-0.61	-0.51	-0.65	0.07	0.75	-0.49	-0.36	-0.88	-0.28	0.55	-0.54	-0.9	-0.87	-0.09	0.56	-0.41	-0.82	-0.2	-0.53	-0.54	-0.54	-0.95		0.64
Retained Earnings Total Equity	-0.73	-0.74	-0.76	-0.72	-0.78	0.57	0.87	-0.87	-0.72	-0.71	-0.34	0.73	-0.75	-0.52	-0.64	0.2	0.74	-0.58	-0.92	0.02	-0.72	-0.74	-0.74	-0.64	0.64

Click cells to compare fundamentals

Acumen Pharmaceuticals Account Relationship Matchups

Pair Trading with Acumen Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acumen Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acumen Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Acumen Stock

0.78	JNJ	Johnson Johnson Financial Report 18th of July 2024	Pair Corr
0.76	NEO	NeoGenomics	Pair Corr

Moving against Acumen Stock

0.68	JPHLF	Japan Post Holdings	Pair Corr
0.47	JPSTF	JAPAN POST BANK	Pair Corr
0.45	MRK	Merck Company Financial Report 6th of August 2024	Pair Corr
0.45	HPQ	HP Inc Fiscal Year End 19th of November 2024	Pair Corr
0.42	MZHOF	Mizuho Financial	Pair Corr

The ability to find closely correlated positions to Acumen Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acumen Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acumen Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acumen Pharmaceuticals to buy it.

The correlation of Acumen Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acumen Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acumen Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Acumen Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Acumen Stock Analysis

When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC